Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety

被引：70

作者：

Dubey, Duvyanshu ^{[1
]}

Kieseier, Bernd C. ^{[2
]}

Hartung, Hans P. ^{[2
]}

Hemmer, Bernhard ^{[3
]}

Warnke, Clemens ^{[2
]}

Menge, Til ^{[2
]}

Miller-Little, William A. ^{[1
]}

Stuve, Olaf ^{[1
,3
,4
]}

机构：

[1] UT Southwestern, Dallas, TX 75235 USA

[2] Univ Dusseldorf, Dusseldorf, Germany

[3] Tech Univ Munich, Munich, Germany

[4] VA North Texas Hlth Care Syst, Dallas, TX USA

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2015年 / 15卷 / 04期

关键词：

dimethyl fumarate; experimental autoimmune encephalomyelitis; immunology; multiple sclerosis; pharmacology; NF-KAPPA-B; PLACEBO-CONTROLLED PHASE-3; ACID ESTERS; MEDICAL PROGRESS; ORAL BG-12; CELLS; SYSTEM; EXPRESSION; PSORIASIS; APOPTOSIS;

D O I：

10.1586/14737175.2015.1025755

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Dimethyl fumarate (DMF), a fumaric acid ester, is a new orally available disease-modifying agent that was recently approved by the US FDA and the EMA for the management of relapsing forms of multiple sclerosis (MS). Fumaric acid has been used for the management of psoriasis, for more than 50 years. Because of the known anti-inflammatory properties of fumaric acid ester, DMF was brought into clinical development in MS. More recently, neuroprotective and myelin-protective mechanism actions have been proposed, making it a possible candidate for MS treatment. Two Phase III clinical trials (DEFINE, CONFIRM) have evaluated the safety and efficacy of DMF in patients with relapsing-remitting MS. Being an orally available agent with a favorable safety profile, it has become one of the most commonly prescribed disease-modifying agents in the USA and Europe.

引用

页码：339 / 346

页数：8

共 60 条

[1]

Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc- as a Neuroprotective Drug Target [J].